Share

In This Section

FDA Approves Trifluridine + Tipiracil with Bevacizumab for Previously Treated mCRC

On August 2, the US Food and Drug Administration (FDA) approved trifluridine and tipiracil with bevacizumab, for metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. 

For more information read the FDA announcement

Posted 8/2/2023